Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype

Click to increase image sizeClick to decrease image size

Author contributions

KA: drafting and writing the manuscript. UA: interpretation of cytogenetic studies and editing the manuscript. ME: interpretation of molecular studies and editing the manuscript. MR: interpretation of flow cytometric studies and editing the manuscript. AD: conceptualization and editing the manuscript. FS: diagnostic review, conceptualization, reviewing, and editing the manuscript.

Disclosure statement

KVA, UA, and FS have no conflicts of interest to disclose. MDE has been on the advisory board for Loxo Oncology. MR has a provision of services to Physicians’ Education Resource, Celgene, and Auron Therapeutics. AD received consultant fees from Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Takeda, EUSA Pharma and research grants from National Cancer Institute, Roche, and Takeda.

Acknowledgements

We would like to thank all the technical personnel in the histology, immunohistochemistry, flow cytometry, cytogenetics, and diagnostic molecular pathology laboratories in the Department of Pathology and Laboratory Medicine, as well as the personnel in the hematologic oncology tissue bank of Memorial Sloan Kettering Cancer Center.